Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates
Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutralizing antibodies (NAbs) against HIV-1. The clinical candidate immunogen ConM SOSIP.v7 is a stabilized native-like HIV-1 Env trimer based on an artificial consensus sequence of all HIV-1 isolates in group M. In preclinical studies ConM SOSIP.v7 trimers induced strong autologous NAb responses in non-human primates (NHPs). To fine-map these responses, we isolated monoclonal antibodies (mAbs) from six cynomolgus macaques that were immunized three times with ConM SOSIP.v7 protein and boosted twice with the closely related ConSOSL.UFO.664 immunogen. A total of 40 ConM and/or ConS-specific mAbs were isolated, of which 18 were retrieved after the three ConM SOSIP.v7 immunizations and 22 after the two immunizations with ConSOSL.UFO.664. 22 mAbs (55%) neutralized the ConM and/or ConS virus. Cross-neutralization of ConS virus by approximately one-third of the mAbs was seen prior to ConSOSL.UFO.664 immunization, albeit with modest potency. Neutralizing antibodies predominantly targeted the V1 and V2 regions of the immunogens, with an apparent extension towards the V3 region. Thus, the V1V2V3 region is immunodominant in the potent NAb response elicited by two consensus sequence native-like HIV-1 Env immunogens. Immunization with these soluble consensus Env proteins also elicited non-neutralizing mAbs targeting the trimer base. These results inform the use and improvement of consensus-based trimer immunogens in combinatorial vaccine strategies.
Reiss, E.I.M.M.
ea9aa03f-b461-4f2c-bf05-5d3cbbe990ca
van Haaren, M.M.
f722e59c-c6b3-4a53-bac7-0ef04913150c
van Schooten, J.
497b0997-1a85-4bdc-b05d-69371835bef3
Claireaux, M.A.F.
ae0eacbf-c01c-4a4a-8ae4-38d24f0a8a35
Maisonnasse, P.
70524e4b-4603-4023-b21d-9854fdcf3487
Antanasijevic, A.
f87b3a62-684c-41e3-8898-5ec80d6d50c3
Allen, J. D.
c89d5569-7659-4835-b535-c9586e956b3a
Bontjer, I.
5c8af5ca-c330-47f2-a0c4-bda0dfdc2a58
Torres, J.L.
8e9a3e7b-a841-4748-927b-967ac8135774
Lee, W. H.
137a13bd-75a4-4b0e-8fad-78ae3bd555d1
Ozorowski, G.
9d448a80-7310-4b30-ba44-ee8b18222a02
Vázquez Bernat, N.
4265ff6d-5641-44cf-9932-9944b7cba1b9
Kaduk, M.
de9c7314-f336-43bf-ab61-269d2572a6f1
Aldon, Y.
be3f0565-c213-44af-973d-3f53b871add4
Burger, J. A.
a72f1372-e14b-410a-980d-526e641ed3dc
Chawla, H.
07b9e983-4c35-4314-999d-fe3222a6c03b
Aartse, A.
9a665668-b010-4c84-8cab-756e1a23776f
Tolazzi, M.
fc80a6b8-b884-4639-9403-05f9af68c681
Gao, H.
6ae951ae-3a7e-4ca1-aab8-d8c43379d0b5
Mundsperger, P.
7fdad456-0d23-4c99-9ac9-631e6700b9c5
Crispin, M.
cd980957-0943-4b89-b2b2-710f01f33bc9
Montefiori, D. C.
e1f1e5f0-7bed-4994-81e2-7f1e0ff5663b
Karlsson Hedestam, G.B.
a379de35-a3da-4264-bee9-01987b8eabaa
Scarlatti, G.
3a2ba4c6-4d7e-4e0d-8018-5dfc3e6bb0cd
Ward, A.B.
78ce5b6a-b852-4ee4-a950-f7ff7b183d83
Le Grand, R.
35e511c8-226d-4f47-8484-0fcf7ad243ca
Shattock, R.
e102792f-de49-4b2c-bf53-ada9f5521603
Dereuddre-Bosquet, N.
9bfa0913-8ff9-43de-9bc5-310cc6f39f0a
Sanders, R.W.
d3b67c2c-c725-42e7-b972-50b30be67c74
van Gils, M.J.
f2e1e7f1-36a1-4270-8509-d17a10ddb9a6
Reiss, E.I.M.M.
ea9aa03f-b461-4f2c-bf05-5d3cbbe990ca
van Haaren, M.M.
f722e59c-c6b3-4a53-bac7-0ef04913150c
van Schooten, J.
497b0997-1a85-4bdc-b05d-69371835bef3
Claireaux, M.A.F.
ae0eacbf-c01c-4a4a-8ae4-38d24f0a8a35
Maisonnasse, P.
70524e4b-4603-4023-b21d-9854fdcf3487
Antanasijevic, A.
f87b3a62-684c-41e3-8898-5ec80d6d50c3
Allen, J. D.
c89d5569-7659-4835-b535-c9586e956b3a
Bontjer, I.
5c8af5ca-c330-47f2-a0c4-bda0dfdc2a58
Torres, J.L.
8e9a3e7b-a841-4748-927b-967ac8135774
Lee, W. H.
137a13bd-75a4-4b0e-8fad-78ae3bd555d1
Ozorowski, G.
9d448a80-7310-4b30-ba44-ee8b18222a02
Vázquez Bernat, N.
4265ff6d-5641-44cf-9932-9944b7cba1b9
Kaduk, M.
de9c7314-f336-43bf-ab61-269d2572a6f1
Aldon, Y.
be3f0565-c213-44af-973d-3f53b871add4
Burger, J. A.
a72f1372-e14b-410a-980d-526e641ed3dc
Chawla, H.
07b9e983-4c35-4314-999d-fe3222a6c03b
Aartse, A.
9a665668-b010-4c84-8cab-756e1a23776f
Tolazzi, M.
fc80a6b8-b884-4639-9403-05f9af68c681
Gao, H.
6ae951ae-3a7e-4ca1-aab8-d8c43379d0b5
Mundsperger, P.
7fdad456-0d23-4c99-9ac9-631e6700b9c5
Crispin, M.
cd980957-0943-4b89-b2b2-710f01f33bc9
Montefiori, D. C.
e1f1e5f0-7bed-4994-81e2-7f1e0ff5663b
Karlsson Hedestam, G.B.
a379de35-a3da-4264-bee9-01987b8eabaa
Scarlatti, G.
3a2ba4c6-4d7e-4e0d-8018-5dfc3e6bb0cd
Ward, A.B.
78ce5b6a-b852-4ee4-a950-f7ff7b183d83
Le Grand, R.
35e511c8-226d-4f47-8484-0fcf7ad243ca
Shattock, R.
e102792f-de49-4b2c-bf53-ada9f5521603
Dereuddre-Bosquet, N.
9bfa0913-8ff9-43de-9bc5-310cc6f39f0a
Sanders, R.W.
d3b67c2c-c725-42e7-b972-50b30be67c74
van Gils, M.J.
f2e1e7f1-36a1-4270-8509-d17a10ddb9a6
Reiss, E.I.M.M., van Haaren, M.M., van Schooten, J., Claireaux, M.A.F., Maisonnasse, P., Antanasijevic, A., Allen, J. D., Bontjer, I., Torres, J.L., Lee, W. H., Ozorowski, G., Vázquez Bernat, N., Kaduk, M., Aldon, Y., Burger, J. A., Chawla, H., Aartse, A., Tolazzi, M., Gao, H., Mundsperger, P., Crispin, M., Montefiori, D. C., Karlsson Hedestam, G.B., Scarlatti, G., Ward, A.B., Le Grand, R., Shattock, R., Dereuddre-Bosquet, N., Sanders, R.W. and van Gils, M.J.
(2022)
Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates.
NPJ Vaccines, 7 (1), [152].
(doi:10.1038/s41541-022-00576-9).
Abstract
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutralizing antibodies (NAbs) against HIV-1. The clinical candidate immunogen ConM SOSIP.v7 is a stabilized native-like HIV-1 Env trimer based on an artificial consensus sequence of all HIV-1 isolates in group M. In preclinical studies ConM SOSIP.v7 trimers induced strong autologous NAb responses in non-human primates (NHPs). To fine-map these responses, we isolated monoclonal antibodies (mAbs) from six cynomolgus macaques that were immunized three times with ConM SOSIP.v7 protein and boosted twice with the closely related ConSOSL.UFO.664 immunogen. A total of 40 ConM and/or ConS-specific mAbs were isolated, of which 18 were retrieved after the three ConM SOSIP.v7 immunizations and 22 after the two immunizations with ConSOSL.UFO.664. 22 mAbs (55%) neutralized the ConM and/or ConS virus. Cross-neutralization of ConS virus by approximately one-third of the mAbs was seen prior to ConSOSL.UFO.664 immunization, albeit with modest potency. Neutralizing antibodies predominantly targeted the V1 and V2 regions of the immunogens, with an apparent extension towards the V3 region. Thus, the V1V2V3 region is immunodominant in the potent NAb response elicited by two consensus sequence native-like HIV-1 Env immunogens. Immunization with these soluble consensus Env proteins also elicited non-neutralizing mAbs targeting the trimer base. These results inform the use and improvement of consensus-based trimer immunogens in combinatorial vaccine strategies.
Text
s41541-022-00576-9
- Version of Record
More information
e-pub ahead of print date: 25 November 2022
Additional Information:
Funding Information:
This work was supported by the European Union’s Horizon 2020 research and innovation program EAVI2020 under grant agreement no. 681137, as well as the HIV Vaccine Research and Design (HIVRAD) program (P01 AI110657) (A.B.W. and R.W.S). Furthermore, this work was supported, in whole or in part, by the Collaboration for AIDS Vaccine Discovery (CAVD) grants OPP1115782, OPP1132237, INV-002022, funded by the Bill and Melinda Gates Foundation. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. R.W.S. is a recipient of a Vici fellowship from the Netherlands Organization for Scientific Research (NWO). M.J.v.G. is supported by an amfAR Mathilde Krim Fellowships in Basic Biomedical Research grant number 109514-61-RKVA and the 2017 AMC Fellowship. Al.A. is supported by amfAR Mathilde Krim Fellowship in Biomedical Research no. 110182-69-RKVA. The neutralization assays performed at Duke University were supported by NIAID-NIH (HHSN272201800004C). The Infectious Disease Models and Innovative Therapies research infrastructure (IDMIT) is supported by the “Program Investissements d’Avenir” (PIA), managed by the ANR under references ANR-11-INBS-0008. The glycopeptide analysis was supported by the CAVD grant INV-008352/OPP1153692 funded by the Bill and Melinda Gates Foundation (M.C.). We are grateful to the staff of IDMIT, particularly to C. Joubert, R. Ho Tsong Fang, B. Delache, S. Langlois, E. Burban, M. Potier, N. Dhooge, J.-M. Robert, M. Barendi, J. Dinh, E. Guyon, S. Keyser and I. Mangeot. G.S., R.W.S, and M.J.v.G. received charitable donations from Fondation Dormeur, Vaduz, for instruments supporting the research of this study. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2022, The Author(s).
Identifiers
Local EPrints ID: 473553
URI: http://eprints.soton.ac.uk/id/eprint/473553
ISSN: 2059-0105
PURE UUID: 43986091-2a3e-4de8-bf2e-c24a994b7acf
Catalogue record
Date deposited: 23 Jan 2023 17:48
Last modified: 12 Jul 2024 02:09
Export record
Altmetrics
Contributors
Author:
E.I.M.M. Reiss
Author:
M.M. van Haaren
Author:
J. van Schooten
Author:
M.A.F. Claireaux
Author:
P. Maisonnasse
Author:
A. Antanasijevic
Author:
I. Bontjer
Author:
J.L. Torres
Author:
W. H. Lee
Author:
G. Ozorowski
Author:
N. Vázquez Bernat
Author:
M. Kaduk
Author:
Y. Aldon
Author:
J. A. Burger
Author:
A. Aartse
Author:
M. Tolazzi
Author:
H. Gao
Author:
P. Mundsperger
Author:
D. C. Montefiori
Author:
G.B. Karlsson Hedestam
Author:
G. Scarlatti
Author:
A.B. Ward
Author:
R. Le Grand
Author:
R. Shattock
Author:
N. Dereuddre-Bosquet
Author:
R.W. Sanders
Author:
M.J. van Gils
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics